In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies.

Close

logo

English
  • Svenska
  • About us
    About us
      • This is Calliditas
      • Vision and Strategy
      • Board of Directors
      • Management Team
      • Corporate Responsibility
      • Our History
  • Disease overview
    Disease overview
      • IgA nephropathy
      • Nefecon
      • Orphan drugs
      • Scientific Advisory Board
  • Governance
    Governance
      • Corporate Structure
      • General Meeting
        • General meetings
      • Nomination Committee
        • Nomination committees
      • Board and Committees
        • Board of Directors
        • Board fees
        • Work of the Board of Directors
        • Committees
      • Management
        • Management team
      • Remuneration
      • Internal control and risk management
      • Auditor
      • Articles of Association
  • Investors
    Investors
      • The share
        • Trading information
        • Ownership structure
        • Share capital development
        • Dividend policy
        • Analyst coverage
      • Financial Reports and Presentations
      • Press releases
      • Calendar
      • Subscribe
      • Contacts
  • Media
    Media
      • Press releases
      • Calliditas in Media
      • Subscribe
      • Contacts
  • Contacts
    Contacts
      • Offices
      • Partnering
      • Investors
      • Media
      • Career
  • IPO
    IPO
      • Press releases
      • Prospectus
      • Key dates
      • Contacts
  • Svenska

Media
Mikael Widell
Mikael Widell
Head of Communications and IR
E-mail: mikael.widell@calliditas.com
Mobile: +46 703 11 99 60
  • Contacts
    • Offices
    • Partnering
    • Investors
    • Media
    • Career

Calliditas Therapeutics AB
Wallingatan 26B
SE-111 24 Stockholm
Sweden

Company number: 556659-9766

  • Privacy policy
  • About cookies

© Calliditas Therapeutics AB 2018